The focus will initially be on creating computational and digital pathology products, as well as AI-assisted algorithms.

AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals ...

March 21 (UPI) --AstraZeneca plans to build a $2.5 billion research and development center in Beijing, the Britain-based multinational pharmaceutical announced Friday. The investment will mark the ...

Novartis and Novo Nordisk — spent more on combined shareholder payments than on research and development. Five of the companies — J&J, Amgen, AstraZeneca, Novartis and Novo Nordisk — spent ...

With the growing understanding that ATTR-CM may be a significant underlying cause of HFpEF, how might AstraZeneca’s research influence the development of therapies for this subset of heart ...

LONDON (Reuters) - AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market ...

"We are also expanding our presence in the United States with significant investments in research, development and manufacturing," said Pascal Soriot, AstraZeneca’s Chief Executive Officer.

Through its recently announced research and development (R&D) expansion, AstraZeneca is focused on tapping into this ecosystem to advance the development of the company’s leading global pipeline ...

[Photo/China Daily] AstraZeneca, a United Kingdom-based biopharmaceutical giant, will add 10 to 15 new projects to the company's research and development pipeline in China each year, reflecting ...